NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 1996
Business Overview: The Company formulates and produces encapsulated vitamins and nutrients, providing marketing services, foreign registration assistance, and graphic design to clients. It focuses on large, financially sound companies with global objectives. The Company operates two wholly-owned subsidiaries, Pro-Lean, Inc. and CellLife International, Inc., which sell proprietary product lines. In 1995, the Company expanded laboratory and quality control capabilities to conform to new United States Pharmacopeia (USP) specifications.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 27.4% ($10.2 million) to a record $47.6 million, driven by increased volume from existing and new customers. International sales rose 43% to $4.3 million.
• Profitability: Net earnings surged 58.9% to $3.2 million. This was aided by a lower effective income tax rate (38.1% vs. 43.4% in 1995) due to a new California investment credit.
• Margins: Gross margins declined slightly from 26.3% to 26.1% due to inventory writedowns on discontinued products. Selling, general, and administrative (SG&A) expenses increased in absolute dollars ($7.2 million vs. $6.2 million) but decreased as a percentage of sales (15.1% vs. 16.6%).
• Cash Flow: Net cash provided by operating activities decreased significantly to $1.1 million from $3.5 million. This was primarily due to a $1.17 million increase in inventory and a $1.33 million decrease in accounts payable.
• Capital Expenditures: Capital spending totaled $2.6 million, primarily for high-speed encapsulating equipment and facility modernization.

Guidance, Outlook, and Risks

• Outlook: Management anticipates capital expenditures of approximately $1.5 million for fiscal 1997. The Company expects to fund these through cash holdings, operating cash flow, and existing lines of credit.
• Backlog: As of September 16, 1996, the backlog was $12.465 million, a slight decline from $13.634 million the prior year, attributed to client ordering patterns.
• Liquidity: The Company maintains $3.0 million in revolving lines of credit with no borrowings outstanding as of June 30, 1996. Management believes current resources are sufficient for anticipated funding requirements.
• Customer Concentration Risk: Three customers (Jenny Craig International, NSA International, and Nu Skin International) represented 69% of sales in 1996. Loss of any of these customers would have a material adverse impact.
• Regulatory Risk: Operations are subject to regulations by the FDA, FTC, and other agencies regarding advertising, labeling, and product safety. Competition is high and expected to increase.
• Related Party Transactions: The Company acquired a building from principal stockholders for $545,000 in June 1996. Additionally, the Company has outstanding notes receivable from the President, Executive Vice President, and Chairman of the Board.

Investor Verification Checklist

• Customer Dependency: Verify the stability of contracts with the top three customers representing 69% of revenue.
• Inventory Levels: Assess the justification for the $1.17 million increase in inventory and the impact of writedowns on discontinued products.
• Cash Flow Divergence: Investigate the significant drop in operating cash flow despite record net earnings.
• Related Party Loans: Review the terms and repayment status of loans to the President, Executive Vice President, and Chairman of the Board.
• Debt Covenants: Confirm continued compliance with financial covenants on the $3.0 million line of credit.